AstraZeneca to Divest European Rights of Crestor (rosuvastatin) to Grünenthal for ~$350M

Shots: Grünenthal to acquire EU rights (Ex- Spain and the UK) of Crestor & its associated brands for ~$350M and will take over bulk production and packaging by 2025. The deal is expected to be closed in Q1’21 The payments will be made in two tranches: $320M will be paid upon transaction closing and $30M …

AstraZeneca to Divest European Rights of Crestor (rosuvastatin) to Grünenthal for ~$350M Read More »